

Dear Fellow Investors,

I hope this note finds you well.

I wanted to provide a few update on our progress since the last investor call:

1. I met yesterday with Aman Chauhan, our Principal Investigator for the Miami trial. He is very excited to start the trial and doing everything possible to move things forward. There are still a number of administrative matters to resolve, but they need to be taken step-by-step over the next couple of months. We are still targeting first patient dosing this summer.
2. We have started the R&D work that needs to be completed prior to starting the Miami trial. It's good to restart work to move us forward.
3. We are progressing on fundraising. We have soft-circled nearly \$2 million for the note that must close by April 22. We initially targeted raising \$1 million in this note that provides a 15% discount to the Series B round and 20% warrant coverage. But we stand by our word that we will take as much as investors are interested in providing by April 22<sup>nd</sup>. If you are interested, please contact Walter Greenblatt ASAP and get everything in by that date to receive the sweeteners.
4. We will formally launch the Series B Preferred round in mid-May and target to close the first tranche as soon as \$3 million (inclusive of the above note) has been identified. At that time, all outstanding notes will convert to Series B Preferred shares.

If you have any questions, please reach to any of us. We look forward to your continued support as we move toward the critical phase of starting the Phase 1/2 trial for SVV-001 to be administered in conjunction with Nivo/Ipi for patients neuroendocrine tumors. We hope to have data by the end of 2025.

Sincerely,

Cuong Do

Executive Chairman